RPG Life Sciences Ltd (RPGLIFE) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- The newly acquired API assets, Actis and Raghuvar, are expected to contribute 25-30 crores in revenue in H2 FY27 with mid-20s EBITDA margins.
- Management has received approval for its Naproxen product in Canada, its first global OTC launch, with shipments starting in December 2026.
- Q2 domestic formulation growth of 11.6% was impacted by a one-time inventory reduction; underlying growth was closer to 15.2% and is expected to rebound.
Performance Overview
- RPG Life Sciences achieved a milestone quarter, crossing 200 crore in quarterly revenue and 50 crore in quarterly EBITDA for the first time.
- Growth was primarily organic, with all three business segments—Domestic Formulations, International Formulations, and API—contributing positively.
- The company completed the strategic acquisition of Actiphers and Raghuvar, significantly expanding its API manufacturing footprint from one to three sites.
- The Domestic Formulations business achieved a top 50 ranking in the Indian Pharma Market, advancing 12 ranks from its position in March 2025.
- Significant investments were made in sales force effectiveness and digital platforms like RPG Serve and RX Star 3.0 to enhance field productivity and doctor engagement.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.